
Chinese General Practice ›› 2024, Vol. 27 ›› Issue (19): 2364-2374.DOI: 10.12114/j.issn.1007-9572.2023.0472
Special Issue: 内分泌代谢性疾病最新文章合辑; 老年问题最新文章合辑; 老年人群健康最新文章合辑
• Article • Previous Articles Next Articles
Received:2023-06-14
Revised:2024-02-26
Published:2024-07-05
Online:2024-04-28
Contact:
ZHU Hong
通讯作者:
朱宏
作者简介:作者贡献:
黄书玮参与文章构思与设计、数据收集与管理、论文写作;周志衡、冯天元、刘莉参与文章构思与设计、数据收集与管理、论文修订;邓光璞、李尧天参与文章构思与设计、统计分析、审查和论文写作;朱宏负责文章构思与设计、文章的质量控制及审校,对文章整体负责。
基金资助:CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2023.0472
| 序号 | 公式 |
|---|---|
| 式(1) | BMI=体质量/身高2 |
| 式(2) | TyG指数=ln[TG×FBG/2] |
| 式(3) | TyG-BMI指数=TyG指数×BMI |
| 式(4) | TyG-WC指数=TyG指数×WC |
| 式(5) | TG/HDL-C指数=TG/HDL-C |
| 式(6) | Non-HDL-C/HDL-C指数=(TC-HDL-C)/HDL-C |
| 式(7) | METS-IR指数= {ln[2×FPG+TG]×BMI/ln [HDL-C]} |
| 式(8) | LCI指数=TC×TG×LDL-C/HDL-C |
| 式(9) | CI指数=(LDL-C-HDL-C)(TG<400 mg/dL)或LDL-C-HDL-C+TG/5(TG≥400 mg/dL) |
Table 1 Indicator calculation formula
| 序号 | 公式 |
|---|---|
| 式(1) | BMI=体质量/身高2 |
| 式(2) | TyG指数=ln[TG×FBG/2] |
| 式(3) | TyG-BMI指数=TyG指数×BMI |
| 式(4) | TyG-WC指数=TyG指数×WC |
| 式(5) | TG/HDL-C指数=TG/HDL-C |
| 式(6) | Non-HDL-C/HDL-C指数=(TC-HDL-C)/HDL-C |
| 式(7) | METS-IR指数= {ln[2×FPG+TG]×BMI/ln [HDL-C]} |
| 式(8) | LCI指数=TC×TG×LDL-C/HDL-C |
| 式(9) | CI指数=(LDL-C-HDL-C)(TG<400 mg/dL)或LDL-C-HDL-C+TG/5(TG≥400 mg/dL) |
| 组别 | 例数 | 性别[例(%)] | 高血压[例(%)] | 吸烟[例(%)] | |||
|---|---|---|---|---|---|---|---|
| 男 | 女 | 否 | 是 | 否 | 是 | ||
| NHUA组 | 1 528 | 838(54.84) | 690(45.16) | 775(49.28) | 753(50.72) | 1 131(74.02) | 387(25.98) |
| HUA组 | 479 | 336(70.15) | 143(29.85) | 184(38.41) | 295(61.59) | 334(69.73) | 145(30.27) |
| χ2值 | 35.177 | 22.136 | 3.403 | ||||
| P值 | <0.001 | <0.001 | 0.065 | ||||
| 组别 | 饮酒[例(%)] | 运动[例(%)] | 年龄( | T2DM病程( | WC( | ||
| 否 | 是 | 否 | 是 | ||||
| NHUA组 | 1 326(86.13) | 212(13.87) | 856(56.02) | 672(43.98) | 57.74±11.15 | 70.86±79.77 | 0.87±0.08 |
| HUA组 | 401(83.72) | 78(16.28) | 243(50.73) | 236(49.27) | 57.62±12.16 | 69.23±66.01 | 0.95±0.06 |
| χ2(t)值 | 1.713a | 4.12a | -0.197 | -0.404 | 19.539 | ||
| P值 | 0.191 | 0.042 | 0.844 | 0.686 | <0.001 | ||
| 组别 | BMI( | SBP( | DBP( | FPG( | HbA1c( | ALT( | AST( |
| NHUA组 | 24.18±2.63 | 130±15 | 79±9 | 7.46±1.45 | 7.48±1.70 | 25.29±6.64 | 22.57±7.02 |
| HUA组 | 26.02±2.97 | 132±15 | 81±9 | 8.01±2.48 | 7.63±2.05 | 27.65±5.05 | 23.82±5.67 |
| t值 | 12.969 | 3.211 | 3.738 | 5.925 | 0.878 | 1.804 | 1.467 |
| P值 | <0.001 | 0.001 | <0.001 | <0.001 | 0.38 | 0.071 | 0.143 |
| 组别 | Scr( | TC( | TG( | LDL-C( | HDL-C( | TyG指数( | TyG-BMI指数( |
| NHUA组 | 68.87±16.54 | 5.01±1.01 | 1.60±1.22 | 3.10±0.97 | 1.53±0.58 | 9.02±0.66 | 218.27±29.52 |
| HUA组 | 85.91±25.49 | 5.16±0.98 | 2.66±1.63 | 3.93±1.51 | 1.19±0.35 | 9.49±0.70 | 247.08±35.58 |
| t值 | 8.37 | 2.835 | 14.014 | 2.133 | -18.025 | 14.626 | 17.711 |
| P值 | <0.001 | 0.005 | <0.001 | 0.033 | <0.001 | <0.001 | <0.001 |
| 组别 | TyG-WC指数( | TG/HDL-C指数( | Non-HDL-C/HDL-C指数( | METS IR指数( | LCI指数( | CI指数( | |
| NHUA组 | 7.89±0.98 | 2.59±1.64 | 2.40±0.90 | 35.90±5.05 | 65 760.34±57 498.98 | 60.66±39.75 | |
| HUA组 | 9.03±0.88 | 5.91±3.61 | 3.60±1.85 | 42.77±7.25 | 176 633.54±368 874.82 | 105.97±58.56 | |
| t值 | 22.844 | 15.92 | 19.049 | 23.215 | 11.324 | 3.004 | |
| P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |
Table 2 Comparison of general information and clinical data between HUA group and NHUA group
| 组别 | 例数 | 性别[例(%)] | 高血压[例(%)] | 吸烟[例(%)] | |||
|---|---|---|---|---|---|---|---|
| 男 | 女 | 否 | 是 | 否 | 是 | ||
| NHUA组 | 1 528 | 838(54.84) | 690(45.16) | 775(49.28) | 753(50.72) | 1 131(74.02) | 387(25.98) |
| HUA组 | 479 | 336(70.15) | 143(29.85) | 184(38.41) | 295(61.59) | 334(69.73) | 145(30.27) |
| χ2值 | 35.177 | 22.136 | 3.403 | ||||
| P值 | <0.001 | <0.001 | 0.065 | ||||
| 组别 | 饮酒[例(%)] | 运动[例(%)] | 年龄( | T2DM病程( | WC( | ||
| 否 | 是 | 否 | 是 | ||||
| NHUA组 | 1 326(86.13) | 212(13.87) | 856(56.02) | 672(43.98) | 57.74±11.15 | 70.86±79.77 | 0.87±0.08 |
| HUA组 | 401(83.72) | 78(16.28) | 243(50.73) | 236(49.27) | 57.62±12.16 | 69.23±66.01 | 0.95±0.06 |
| χ2(t)值 | 1.713a | 4.12a | -0.197 | -0.404 | 19.539 | ||
| P值 | 0.191 | 0.042 | 0.844 | 0.686 | <0.001 | ||
| 组别 | BMI( | SBP( | DBP( | FPG( | HbA1c( | ALT( | AST( |
| NHUA组 | 24.18±2.63 | 130±15 | 79±9 | 7.46±1.45 | 7.48±1.70 | 25.29±6.64 | 22.57±7.02 |
| HUA组 | 26.02±2.97 | 132±15 | 81±9 | 8.01±2.48 | 7.63±2.05 | 27.65±5.05 | 23.82±5.67 |
| t值 | 12.969 | 3.211 | 3.738 | 5.925 | 0.878 | 1.804 | 1.467 |
| P值 | <0.001 | 0.001 | <0.001 | <0.001 | 0.38 | 0.071 | 0.143 |
| 组别 | Scr( | TC( | TG( | LDL-C( | HDL-C( | TyG指数( | TyG-BMI指数( |
| NHUA组 | 68.87±16.54 | 5.01±1.01 | 1.60±1.22 | 3.10±0.97 | 1.53±0.58 | 9.02±0.66 | 218.27±29.52 |
| HUA组 | 85.91±25.49 | 5.16±0.98 | 2.66±1.63 | 3.93±1.51 | 1.19±0.35 | 9.49±0.70 | 247.08±35.58 |
| t值 | 8.37 | 2.835 | 14.014 | 2.133 | -18.025 | 14.626 | 17.711 |
| P值 | <0.001 | 0.005 | <0.001 | 0.033 | <0.001 | <0.001 | <0.001 |
| 组别 | TyG-WC指数( | TG/HDL-C指数( | Non-HDL-C/HDL-C指数( | METS IR指数( | LCI指数( | CI指数( | |
| NHUA组 | 7.89±0.98 | 2.59±1.64 | 2.40±0.90 | 35.90±5.05 | 65 760.34±57 498.98 | 60.66±39.75 | |
| HUA组 | 9.03±0.88 | 5.91±3.61 | 3.60±1.85 | 42.77±7.25 | 176 633.54±368 874.82 | 105.97±58.56 | |
| t值 | 22.844 | 15.92 | 19.049 | 23.215 | 11.324 | 3.004 | |
| P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |
| 变量 | B | SE | OR(95%CI) | Wald χ2值 | P值 |
|---|---|---|---|---|---|
| 性别(以男性为对照) | |||||
| 女性 | -0.660 | 0.112 | 0.517(0.415~0.644) | 34.533 | <0.001 |
| 吸烟(以不吸烟为对照) | |||||
| 吸烟 | 0.213 | 0.115 | 1.237(0.987~1.550) | 3.397 | 0.065 |
| 饮酒(以不喝酒为对照) | |||||
| 喝酒 | 0.189 | 0.144 | 1.207(0.910~1.602) | 1.709 | 0.191 |
| 运动(以不锻炼为对照) | |||||
| 锻炼 | 0.213 | 0.105 | 0.808(0.658~0.993) | 4.113 | 0.043 |
| 高血压(以非高血压为对照) | |||||
| 高血压 | 0.501 | 0.107 | 1.650(1.338~2.035) | 21.921 | <0.001 |
| 年龄 | -0.001 | 0.005 | 0.999(0.990~1.008) | 0.039 | 0.844 |
| 病程 | 0.000 | 0.001 | 1.000(0.998~1.001) | 0.163 | 0.686 |
| WC | 0.145 | 0.009 | 1.156(1.136~1.176) | 263.989 | <0.001 |
| BMI | 0.233 | 0.020 | 1.262(1.214~1.312) | 136.975 | <0.001 |
| SBP | 0.011 | 0.004 | 1.011(1.004~1.019) | 10.207 | 0.001 |
| DBP | 0.021 | 0.006 | 1.021(1.010~1.033) | 13.766 | <0.001 |
| FPG | 0.162 | 0.028 | 1.176(1.112~1.244) | 32.427 | <0.001 |
| HbA1c | 0.012 | 0.014 | 1.012(0.984~1.040) | 0.675 | 0.411 |
| ALT | 0.003 | 0.002 | 1.003(0.999~1.007) | 2.733 | 0.098 |
| AST | 0.004 | 0.003 | 1.004(0.998~1.010) | 1.862 | 0.172 |
| Scr | 0.016 | 0.002 | 1.016(1.012~1.020) | 60.549 | <0.001 |
| TC | 0.144 | 0.051 | 1.154(1.044~1.276) | 7.902 | 0.005 |
| TG | 0.645 | 0.053 | 1.905(1.716~2.115) | 146.439 | <0.001 |
| LDL-C | 0.149 | 0.055 | 1.161(1.041~1.294) | 7.239 | 0.007 |
| HDL-C | -3.699 | 0.223 | 0.250(0.160~0.380) | 275.394 | <0.001 |
| TyG指数 | 1.213 | 0.094 | 3.365(2.796~4.049) | 165.149 | <0.001 |
| TyG-BMI指数 | 0.028 | 0.002 | 1.029(1.025~1.032) | 221.724 | <0.001 |
| TyG-WC指数 | 1.310 | 0.074 | 3.705(3.204~4.285) | 311.638 | <0.001 |
| TG/HDL-C指数 | 0.398 | 0.027 | 1.489(1.411~1.571) | 211.636 | <0.001 |
| Non-HDL-C/HDL-C指数 | 1.110 | 0.063 | 3.034(2.680~3.436) | 126.324 | <0.001 |
| METS_IR指数 | 0.205 | 0.012 | 1.228(1.200~1.256) | 308.428 | <0.001 |
| LCI指数 | 0.000 | 0.000 | 1.000(1.000~1.000) | 169.924 | <0.001 |
| CI指数 | 0.014 | 0.002 | 1.014(1.011~1.017) | 75.331 | <0.001 |
Table 3 Univariate Logistic regression analysis of HUA occurrence in middle-aged and elderly T2DM patients
| 变量 | B | SE | OR(95%CI) | Wald χ2值 | P值 |
|---|---|---|---|---|---|
| 性别(以男性为对照) | |||||
| 女性 | -0.660 | 0.112 | 0.517(0.415~0.644) | 34.533 | <0.001 |
| 吸烟(以不吸烟为对照) | |||||
| 吸烟 | 0.213 | 0.115 | 1.237(0.987~1.550) | 3.397 | 0.065 |
| 饮酒(以不喝酒为对照) | |||||
| 喝酒 | 0.189 | 0.144 | 1.207(0.910~1.602) | 1.709 | 0.191 |
| 运动(以不锻炼为对照) | |||||
| 锻炼 | 0.213 | 0.105 | 0.808(0.658~0.993) | 4.113 | 0.043 |
| 高血压(以非高血压为对照) | |||||
| 高血压 | 0.501 | 0.107 | 1.650(1.338~2.035) | 21.921 | <0.001 |
| 年龄 | -0.001 | 0.005 | 0.999(0.990~1.008) | 0.039 | 0.844 |
| 病程 | 0.000 | 0.001 | 1.000(0.998~1.001) | 0.163 | 0.686 |
| WC | 0.145 | 0.009 | 1.156(1.136~1.176) | 263.989 | <0.001 |
| BMI | 0.233 | 0.020 | 1.262(1.214~1.312) | 136.975 | <0.001 |
| SBP | 0.011 | 0.004 | 1.011(1.004~1.019) | 10.207 | 0.001 |
| DBP | 0.021 | 0.006 | 1.021(1.010~1.033) | 13.766 | <0.001 |
| FPG | 0.162 | 0.028 | 1.176(1.112~1.244) | 32.427 | <0.001 |
| HbA1c | 0.012 | 0.014 | 1.012(0.984~1.040) | 0.675 | 0.411 |
| ALT | 0.003 | 0.002 | 1.003(0.999~1.007) | 2.733 | 0.098 |
| AST | 0.004 | 0.003 | 1.004(0.998~1.010) | 1.862 | 0.172 |
| Scr | 0.016 | 0.002 | 1.016(1.012~1.020) | 60.549 | <0.001 |
| TC | 0.144 | 0.051 | 1.154(1.044~1.276) | 7.902 | 0.005 |
| TG | 0.645 | 0.053 | 1.905(1.716~2.115) | 146.439 | <0.001 |
| LDL-C | 0.149 | 0.055 | 1.161(1.041~1.294) | 7.239 | 0.007 |
| HDL-C | -3.699 | 0.223 | 0.250(0.160~0.380) | 275.394 | <0.001 |
| TyG指数 | 1.213 | 0.094 | 3.365(2.796~4.049) | 165.149 | <0.001 |
| TyG-BMI指数 | 0.028 | 0.002 | 1.029(1.025~1.032) | 221.724 | <0.001 |
| TyG-WC指数 | 1.310 | 0.074 | 3.705(3.204~4.285) | 311.638 | <0.001 |
| TG/HDL-C指数 | 0.398 | 0.027 | 1.489(1.411~1.571) | 211.636 | <0.001 |
| Non-HDL-C/HDL-C指数 | 1.110 | 0.063 | 3.034(2.680~3.436) | 126.324 | <0.001 |
| METS_IR指数 | 0.205 | 0.012 | 1.228(1.200~1.256) | 308.428 | <0.001 |
| LCI指数 | 0.000 | 0.000 | 1.000(1.000~1.000) | 169.924 | <0.001 |
| CI指数 | 0.014 | 0.002 | 1.014(1.011~1.017) | 75.331 | <0.001 |
| 变量 | 模型1 | 模型2 | 模型3 | |||
|---|---|---|---|---|---|---|
| OR(95%CI) | P值 | OR(95%CI) | P值 | OR(95%CI) | P值 | |
| BMI | 1.072(1.021~1.125) | 0.005 | 1.081(1.031~1.133) | <0.001 | ||
| WC | 1.130(1.108~1.153) | <0.001 | 1.118(1.097~1.140) | <0.001 | ||
| Scr | 1.014(1.010~1.018) | <0.001 | 1.014(1.010~1.018) | <0.001 | 1.014(1.010~1.018) | <0.001 |
| TyG指数 | 2.849(2.347~3.561) | <0.001 | ||||
| TyG-BMI指数 | 1.018(1.014~1.023) | <0.001 | ||||
| TyG-WC指数 | 3.411(2.916~3.991) | <0.001 | ||||
| 变量 | 模型4 | 模型5 | 模型6 | |||
| OR(95%CI) | P值 | OR(95%CI) | P值 | OR(95%CI) | P值 | |
| BMI | 1.064(1.013~1.119) | 0.014 | 1.061(1.008~1.116) | <0.001 | ||
| WC | 1.132(1.109~1.156) | <0.001 | 1.140(1.116~1.164) | <0.001 | 1.103(1.081~1.125) | <0.001 |
| Scr | 1.012(1.008~1.016) | <0.001 | 1.011(1.007~1.015) | <0.001 | 1.013(1.008~1.017) | <0.001 |
| TG/HDL-C指数 | 1.425(1.344~1.510) | <0.001 | ||||
| Non-HDL-C/HDL-C指数 | 2.847(2.483~3.264) | <0.001 | ||||
| METS-IR指数 | 1.170(1.142~1.200) | <0.001 | ||||
Table 4 Multivariate Logistic regression analysis of HUA occurrence in middle-aged and elderly T2DM patients
| 变量 | 模型1 | 模型2 | 模型3 | |||
|---|---|---|---|---|---|---|
| OR(95%CI) | P值 | OR(95%CI) | P值 | OR(95%CI) | P值 | |
| BMI | 1.072(1.021~1.125) | 0.005 | 1.081(1.031~1.133) | <0.001 | ||
| WC | 1.130(1.108~1.153) | <0.001 | 1.118(1.097~1.140) | <0.001 | ||
| Scr | 1.014(1.010~1.018) | <0.001 | 1.014(1.010~1.018) | <0.001 | 1.014(1.010~1.018) | <0.001 |
| TyG指数 | 2.849(2.347~3.561) | <0.001 | ||||
| TyG-BMI指数 | 1.018(1.014~1.023) | <0.001 | ||||
| TyG-WC指数 | 3.411(2.916~3.991) | <0.001 | ||||
| 变量 | 模型4 | 模型5 | 模型6 | |||
| OR(95%CI) | P值 | OR(95%CI) | P值 | OR(95%CI) | P值 | |
| BMI | 1.064(1.013~1.119) | 0.014 | 1.061(1.008~1.116) | <0.001 | ||
| WC | 1.132(1.109~1.156) | <0.001 | 1.140(1.116~1.164) | <0.001 | 1.103(1.081~1.125) | <0.001 |
| Scr | 1.012(1.008~1.016) | <0.001 | 1.011(1.007~1.015) | <0.001 | 1.013(1.008~1.017) | <0.001 |
| TG/HDL-C指数 | 1.425(1.344~1.510) | <0.001 | ||||
| Non-HDL-C/HDL-C指数 | 2.847(2.483~3.264) | <0.001 | ||||
| METS-IR指数 | 1.170(1.142~1.200) | <0.001 | ||||
| 变量 | OR(95%CI) | P值 | |
|---|---|---|---|
| TyG指数 | Q1 | ||
| Q2 | 1.543(0.937~2.149) | <0.084 | |
| Q3 | 2.487(1.628~3.346) | <0.001 | |
| Q4 | 3.941(2.286~5.435) | <0.001 | |
| TyG-BMI指数 | Q1 | ||
| Q2 | 2.252(1.420~3.572) | 0.001 | |
| Q3 | 2.949(1.883~4.617) | <0.001 | |
| Q4 | 4.735(3.035~7.389) | <0.001 | |
| TyG-WC指数 | Q1 | ||
| Q2 | 2.955(2.201~3.709) | <0.001 | |
| Q3 | 3.509(2.462~4.556) | <0.001 | |
| Q4 | 5.184(3.850~6.518) | <0.001 | |
| TG/HDL-C指数 | Q1 | ||
| Q2 | 1.034(0.726~1.342) | 0.297 | |
| Q3 | 2.863(2.023~3.703) | <0.001 | |
| Q4 | 3.554(2.421~4.687) | <0.001 | |
| Non HDL-C/HDL-C指数 | Q1 | ||
| Q2 | 1.443(0.720~2.889) | 0.301 | |
| Q3 | 2.551(1.482~4.390) | <0.001 | |
| Q4 | 4.375(2.337~8.192) | <0.001 | |
| METS-IR指数 | Q1 | ||
| Q2 | 2.568(1.526~4.322) | <0.001 | |
| Q3 | 3.473(2.097~5.752) | <0.001 | |
| Q4 | 4.725(2.453~6.997) | <0.001 |
Table 5 Multivariate Logistic regression analysis of 6 insulin resistance replacement indexes for the occurrence of HUA
| 变量 | OR(95%CI) | P值 | |
|---|---|---|---|
| TyG指数 | Q1 | ||
| Q2 | 1.543(0.937~2.149) | <0.084 | |
| Q3 | 2.487(1.628~3.346) | <0.001 | |
| Q4 | 3.941(2.286~5.435) | <0.001 | |
| TyG-BMI指数 | Q1 | ||
| Q2 | 2.252(1.420~3.572) | 0.001 | |
| Q3 | 2.949(1.883~4.617) | <0.001 | |
| Q4 | 4.735(3.035~7.389) | <0.001 | |
| TyG-WC指数 | Q1 | ||
| Q2 | 2.955(2.201~3.709) | <0.001 | |
| Q3 | 3.509(2.462~4.556) | <0.001 | |
| Q4 | 5.184(3.850~6.518) | <0.001 | |
| TG/HDL-C指数 | Q1 | ||
| Q2 | 1.034(0.726~1.342) | 0.297 | |
| Q3 | 2.863(2.023~3.703) | <0.001 | |
| Q4 | 3.554(2.421~4.687) | <0.001 | |
| Non HDL-C/HDL-C指数 | Q1 | ||
| Q2 | 1.443(0.720~2.889) | 0.301 | |
| Q3 | 2.551(1.482~4.390) | <0.001 | |
| Q4 | 4.375(2.337~8.192) | <0.001 | |
| METS-IR指数 | Q1 | ||
| Q2 | 2.568(1.526~4.322) | <0.001 | |
| Q3 | 3.473(2.097~5.752) | <0.001 | |
| Q4 | 4.725(2.453~6.997) | <0.001 |
| 变量 | AUC | OR(95%CI) | 灵敏度(%) | 特异度(%) | 最佳截断值 | 约登指数 |
|---|---|---|---|---|---|---|
| TyG指数 | 0.677 | (0.650,0.703) | 89.80 | 65.30 | 8.78 | 0.245 |
| TyG-BMI指数 | 0.731 | (0.706,0.756) | 59.50 | 25.90 | 234.90 | 0.336 |
| TyG-WC指数 | 0.811 | (0.792,0.830) | 84.80 | 37.90 | 8.20 | 0.469 |
| TG/HDL-C指数 | 0.757 | (0.733,0.780) | 82.30 | 45.70 | 2.28 | 0.366 |
| Non-HDL-C/HDL-C指数 | 0.796 | (0.773,0.819) | 77.50 | 30.30 | 2.76 | 0.472 |
| METS-IR指数 | 0.791 | (0.768,0.814) | 64.50 | 22.00 | 39.61 | 0.425 |
| 男性 | ||||||
| TyG指数 | 0.655 | (0.622,0.688) | 88.70 | 65.90 | 8.77 | 0.228 |
| TyG-BMI指数 | 0.701 | (0.669,0.733) | 58.60 | 29.70 | 234.48 | 0.289 |
| TyG-WC指数 | 0.770 | (0.742,0.797) | 72.60 | 34.10 | 8.46 | 0.385 |
| TG/HDL-C指数 | 0.733 | (0.703,0.763) | 84.20 | 49.30 | 2.28 | 0.349 |
| Non-HDL-C/HDL-C指数 | 0.785 | (0.756,0.814) | 75.90 | 30.70 | 2.82 | 0.452 |
| METS-IR指数 | 0.765 | (0.735,0.795) | 62.80 | 23.30 | 40.16 | 0.395 |
| 女性 | ||||||
| TyG指数 | 0.719 | (0.675,0.763) | 66.40 | 37.00 | 9.20 | 0.294 |
| TyG-BMI指数 | 0.770 | (0.737,0.817) | 67.80 | 25.50 | 232.53 | 0.423 |
| TyG-WC指数 | 0.864 | (0.838,0.890) | 87.40 | 26.80 | 8.28 | 0.606 |
| TG/HDL-C指数 | 0.782 | (0.742,0.822) | 51.70 | 11.90 | 3.97 | 0.398 |
| Non-HDL-C/HDL-C指数 | 0.808 | (0.771,0.845) | 78.30 | 26.70 | 2.76 | 0.516 |
| METS-IR指数 | 0.822 | (0.786,0.857) | 81.80 | 33.00 | 36.81 | 0.488 |
Table 6 ROC curve and subgroup analysis of different insulin resistance replacement indexes for the risk of HUA in T2DM patients
| 变量 | AUC | OR(95%CI) | 灵敏度(%) | 特异度(%) | 最佳截断值 | 约登指数 |
|---|---|---|---|---|---|---|
| TyG指数 | 0.677 | (0.650,0.703) | 89.80 | 65.30 | 8.78 | 0.245 |
| TyG-BMI指数 | 0.731 | (0.706,0.756) | 59.50 | 25.90 | 234.90 | 0.336 |
| TyG-WC指数 | 0.811 | (0.792,0.830) | 84.80 | 37.90 | 8.20 | 0.469 |
| TG/HDL-C指数 | 0.757 | (0.733,0.780) | 82.30 | 45.70 | 2.28 | 0.366 |
| Non-HDL-C/HDL-C指数 | 0.796 | (0.773,0.819) | 77.50 | 30.30 | 2.76 | 0.472 |
| METS-IR指数 | 0.791 | (0.768,0.814) | 64.50 | 22.00 | 39.61 | 0.425 |
| 男性 | ||||||
| TyG指数 | 0.655 | (0.622,0.688) | 88.70 | 65.90 | 8.77 | 0.228 |
| TyG-BMI指数 | 0.701 | (0.669,0.733) | 58.60 | 29.70 | 234.48 | 0.289 |
| TyG-WC指数 | 0.770 | (0.742,0.797) | 72.60 | 34.10 | 8.46 | 0.385 |
| TG/HDL-C指数 | 0.733 | (0.703,0.763) | 84.20 | 49.30 | 2.28 | 0.349 |
| Non-HDL-C/HDL-C指数 | 0.785 | (0.756,0.814) | 75.90 | 30.70 | 2.82 | 0.452 |
| METS-IR指数 | 0.765 | (0.735,0.795) | 62.80 | 23.30 | 40.16 | 0.395 |
| 女性 | ||||||
| TyG指数 | 0.719 | (0.675,0.763) | 66.40 | 37.00 | 9.20 | 0.294 |
| TyG-BMI指数 | 0.770 | (0.737,0.817) | 67.80 | 25.50 | 232.53 | 0.423 |
| TyG-WC指数 | 0.864 | (0.838,0.890) | 87.40 | 26.80 | 8.28 | 0.606 |
| TG/HDL-C指数 | 0.782 | (0.742,0.822) | 51.70 | 11.90 | 3.97 | 0.398 |
| Non-HDL-C/HDL-C指数 | 0.808 | (0.771,0.845) | 78.30 | 26.70 | 2.76 | 0.516 |
| METS-IR指数 | 0.822 | (0.786,0.857) | 81.80 | 33.00 | 36.81 | 0.488 |
| 变量 | HUA | NHUA | 合计 |
|---|---|---|---|
| TyG-WC指数 | |||
| 高 | 42 | 371 | 413 |
| 低 | 32 | 510 | 542 |
| 合计 | 74 | 881 | 955 |
| Non-HDL-C/HDL-C指数 | |||
| 高 | 46 | 430 | 476 |
| 低 | 28 | 451 | 479 |
| 合计 | 74 | 881 | 955 |
| METS-IR指数 | |||
| 高 | 36 | 318 | 354 |
| 低 | 38 | 563 | 601 |
| 合计 | 74 | 881 | 955 |
Table 7 Nested case-control analysis of HUA occurrence
| 变量 | HUA | NHUA | 合计 |
|---|---|---|---|
| TyG-WC指数 | |||
| 高 | 42 | 371 | 413 |
| 低 | 32 | 510 | 542 |
| 合计 | 74 | 881 | 955 |
| Non-HDL-C/HDL-C指数 | |||
| 高 | 46 | 430 | 476 |
| 低 | 28 | 451 | 479 |
| 合计 | 74 | 881 | 955 |
| METS-IR指数 | |||
| 高 | 36 | 318 | 354 |
| 低 | 38 | 563 | 601 |
| 合计 | 74 | 881 | 955 |
| 变量 | 血糖控制不佳 | 血糖控制良好 | 合计 |
|---|---|---|---|
| TyG-WC指数 | |||
| 高 | 221 | 192 | 413 |
| 低 | 145 | 397 | 542 |
| 合计 | 366 | 589 | 955 |
| Non-HDL-C/HDL-C指数 | |||
| 高 | 216 | 260 | 476 |
| 低 | 150 | 329 | 479 |
| 合计 | 366 | 589 | 955 |
| METS-IR指数 | |||
| 高 | 186 | 168 | 354 |
| 低 | 180 | 421 | 601 |
| 合计 | 366 | 589 | 955 |
Table 8 Nested case-control study of blood glucose control in diabetic patients
| 变量 | 血糖控制不佳 | 血糖控制良好 | 合计 |
|---|---|---|---|
| TyG-WC指数 | |||
| 高 | 221 | 192 | 413 |
| 低 | 145 | 397 | 542 |
| 合计 | 366 | 589 | 955 |
| Non-HDL-C/HDL-C指数 | |||
| 高 | 216 | 260 | 476 |
| 低 | 150 | 329 | 479 |
| 合计 | 366 | 589 | 955 |
| METS-IR指数 | |||
| 高 | 186 | 168 | 354 |
| 低 | 180 | 421 | 601 |
| 合计 | 366 | 589 | 955 |
| [1] |
|
| [2] |
中华医学会糖尿病学分会胰岛素抵抗学组(筹). 胰岛素抵抗评估方法和应用的专家指导意见[J]. 中华糖尿病杂志,2018,10(6):377-385. DOI:10.3760/cma.j.issn.1674-5809.2018.06.001.
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
宋华隆,高鹰. 血尿酸水平与2型糖尿病发病风险的关联队列研究[J]. 中国全科医学,2023,26(15):1831-1839. DOI:10.12114/j.issn.1007-9572.2022.0785.
|
| [11] |
段琼,张紫行,徐娟,等. 高尿酸血症与脂肪肝关联的前瞻性队列研究[J]. 中华疾病控制杂志,2022,26(12):1420-1425,1432. DOI:10.16462/j.cnki.zhjbkz.2022.12.010.
|
| [12] |
|
| [13] |
李歆旎,沈艳,金雪娟,等. 血尿酸与高血压的相关性研究[J]. 中国分子心脏病学杂志,2022,22(5):4897-4902. DOI:10.16563/j.cnki.1671-6272.2022.10.005.
|
| [14] |
|
| [15] |
|
| [16] |
中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 国际内分泌代谢杂志,2021,41(5):482-548. DOI:10.3760/cma.j.cn121383-20210825-08063.
|
| [17] |
中华医学会内分泌学分会. 中国高尿酸血症与痛风诊疗指南(2019)[J]. 中华内分泌代谢杂志,2020,36(1):1-13. DOI:10.3760/cma.j.issn.1000-6699.2020.01.001.
|
| [18] | |
| [19] |
中国疾病预防控制中心. 中国慢性病及其危险因素监测分析报告2004年[M]. 北京:中国协和医科大学出版社,2009.
|
| [20] |
|
| [21] | |
| [22] |
|
| [23] |
刘颖. 高尿酸对3T3-L1脂肪细胞IRS-1表达及其酪氨酸磷酸化水平的影响[D]. 长沙:中南大学,2013.
|
| [24] |
董洋,赵心迪,曹慧霞,等. 2型糖尿病患者血尿酸水平与肾功能损伤的相关性[J]. 中华实用诊断与治疗杂志,2022,36(5):456-459. DOI:10.13507/j.issn.1674-3474.2022.05.005.
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] | |
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
杨媛,周光清,李宛霖,等. 不同肥胖指标在高尿酸血症风险预测中的应用价值比较研究[J]. 中国全科医学,2022,25(4):453-460. DOI:10.12114/j.issn.1007-9572.2021.00.281.
|
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
|
| [45] | |
| [46] |
赵美茹,朱迪,刘淋,等. 简易胰岛素抵抗指标与698例2型糖尿病患者发生高尿酸血症风险的关联[J]. 山东大学学报(医学版),2022,60(12):44-51. DOI:10.6040/j.issn.1671-7554.0.2022.0575.
|
| [1] | CHAI Zhihao, ZHANG Weisen, LUO Jiaoling, ZHU Feng, ZHU Tong, JIN Yali, PAN Jing, LU Yingjun, JIANG Chaoqiang. The Mediation Effect of Socioeconomic Status in Childhood Parental Literacy and Cognitive Function in Middle-aged and Older People: Based on Guangzhou Biobank Cohort Study [J]. Chinese General Practice, 2026, 29(21): 2959-2966. |
| [2] | LI Wenping, CHEN Jianhua, XU Jiapei, JIN Xue, PAN Zihan, CHI Chunhua. A Scoping Review on the Empowerment of Community Elderly Health Services by Digital-Intelligent Health Management Platforms [J]. Chinese General Practice, 2026, 29(21): 2938-2949. |
| [3] | LI Feng, HU Changhao, LUO Xu. Progress in the Study of Influencing Factors and Intervention Strategies of Mental Health in Elderly Patients with Multiple Chronic Conditions [J]. Chinese General Practice, 2026, 29(20): 2816-2828. |
| [4] | PANG Shu, SUN ying, JIANG Chunyan. Comparison of the Effectiveness of Fried's Frailty Phenotype and the FRAIL Scale in Assessing Pre-frailty among Community-dwelling Older Adults Undergoing Health Examinations [J]. Chinese General Practice, 2026, 29(19): 2664-2670. |
| [5] | LI Simin, ZHANG Tingting, WANG Kunbo, YANG Jianzhou, PING Weiwei. Effects of Exercise Dosage on Elderly Patients with Sarcopenia: a Meta-analysis [J]. Chinese General Practice, 2026, 29(17): 2400-2409. |
| [6] | CHEN Yan, SHEN Dequan, SHENG Renlei, CHANG Yujie, YANG Jiaqi, DING Jie, SUN Zhifang, WANG Dahui. Influencing Factors and Importance Ranking of the Utilization of Primary-level Traditional Chinese Medicine Preventive and Health Care Services for the Elderly [J]. Chinese General Practice, 2026, 29(16): 2182-2189. |
| [7] | YU Shan, CHE Yajie, SUBIYINUER· Maimaiti, GUO Kaiyang, FENG Xingxing, YAN Ping. A Comparative Study on the Current Situation and Influencing Factors of Subjective Cognitive Decline among Urban and Rural Elderly People in Xinjiang [J]. Chinese General Practice, 2026, 29(16): 2227-2233. |
| [8] | YANG Tingting, ZHENG Li, LIANG Daqiang, WU fan, YUAN Xianxian, WEI lai, HU Jin, WANG Junhua, WANG Ziyun. Association between Sleep Fragmentation and Arteriosclerosis among Population Aged 40-65 Years [J]. Chinese General Practice, 2026, 29(16): 2190-2197. |
| [9] | LI Jiali, LIU Fan, KE Lixin, LI Huijuan, WANG Haibo, ZHAO Xiaoxiao, ZHAO Xinke, LU Cuncun. Disease Burden of Obesity among Individuals Aged 60 and above Globally and in China from 1990 to 2021: Trend Analysis and Model-based Projection [J]. Chinese General Practice, 2026, 29(15): 2067-2076. |
| [10] | WU Zhiyuan, WANG Chuanxu, YANG Feng, ZHANG Xuming, ZHOU Jiabao, GAO Jiandong. Study on the Mechanism of Shizhi Fang in Uric Acid Transport-related Proteins in Hyperuricemia [J]. Chinese General Practice, 2026, 29(14): 1898-1910. |
| [11] | JIAO Shuting, ZHAO Yali. A Qualitative Study on the Current Status of Chronic Pruritus Services for the Elderly in Community [J]. Chinese General Practice, 2026, 29(13): 1682-1687. |
| [12] | XIANG Tong, HUANG Yafang, WU Hao. Investigation Study on Older People's Willingness to Use Webcast Exercise Guidance: Based on the UTAUT Model and the Perceived Risk Theory [J]. Chinese General Practice, 2026, 29(13): 1720-1725. |
| [13] | LI Jing, JI Yan, SUN Liu, WANG Hanting, WU Jidong, LIU June. Summary of Best Evidence on the Management of Hearing Loss in Older Adults in Primary Health Care Settings [J]. Chinese General Practice, 2026, 29(13): 1713-1719. |
| [14] | CHEN Yiming, HUANG Yiling, JI Fei, LYU Ling, HUANG Yu, WU Zeyu, HANG Qiqi, PING Fan, YANG Meng. Hepatic-glycemic Interdependence: the Bidirectional Relationship between Type 2 Diabetes and MASLD and Emerging Therapeutic Strategies [J]. Chinese General Practice, 2026, 29(12): 1497-1504. |
| [15] | LI Li, XU Tianchao, DONG Xiaomei, HUANG Hongfei, CUI Gang, LI Dongdong, ZHANG Ou, FAN Lin, WANG Qi. The Effect of Kidney Tonifying and Brain Strengthening Acupuncture Combined with Sertraline in the Treatment of Elderly Depression: a Randomized Controlled Trial [J]. Chinese General Practice, 2026, 29(11): 1399-1404. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||